The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an osteoarthritis treatment in human trials may have potential for treating RA.

Isomyosamine targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia. "Findings from the initial observational study will inform our forward move into multiple planned clinical ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during ...